Fundraisings and IPOs

Date: 2018-10-17

Type of information: Series B financing round

Company: Acticor Biotech (France)

Investors: Newton BioCapital (Belgium) CapDecisif Management (France) Mirae Capital (South Korea) CMS Medical Venture Investment (China) A&B (China)

Amount: € 15.3 million

Funding type: series B financing round

Planned used:

  • Acticor Biotech is a clinical stage biotechnology company, spin-off of INSERM, dedicated to developing an innovative treatment in the therapy of acute thrombotic diseases, including ischemic stroke and pulmonary embolism. The company is built upon the expertise and the results of researches conducted by, the founders: Dr. Martine Jandrot-Perrus at INSERM Paris and Pr. Philippe Billiald at Paris-Sud University.
  • The financing will support the advancement of ACT017 into its first phase II clinical development in acute ischemic stroke. ACT017 is a humanized Antibody Fragment (Fab) directed against a novel target of major interest, platelet glycoprotein VI (GPVI), and inhibits its action. Evidence of antithrombotic efficacy of ACT017 and safety of inhibition of GPVI have been established both ex vivo and in vivo. The target is involved in the growth of the thrombus, but not in physiological haemostasis. This limits the bleeding risk associated with its inhibition.


  • On October 17, 2018, Acticor Biotech announced that it has completed a €15.3 million Series B round of financing from European and Asian investors. This new funding will enable the company to finance its first phase II in acute ischemic stroke with its lead candidate ACT017. The Series B was led by Newton BioCapital, a Belgium venture capital fund, followed by Mirae Capital, a Korean fund, CMS Medical Venture Investment Limited and A&B (HK), these last two funds are based in Hong Kong. Existing investors including CapDecisif Management also participated into this round.
  • This Series B might be completed by an additional financing of up to €5M in order to finance additional clinical developments with ACT017 in other indication.

Therapeutic area: Cerebrovascular diseases

Is general: Yes